Loading…
Alaunos Therapeutics, Inc. is projected to decline to $1.93 by 2027, a -7% move from its current price of $2.07. TCRT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.99 | $2.07 | $2.15 | 0.00% |
| Jul 13 | $1.96 | $2.07 | $2.19 | +0.01% |
| Jul 14 | $1.93 | $2.07 | $2.22 | +0.01% |
| Jul 15 | $1.91 | $2.07 | $2.24 | +0.02% |
| Jul 16 | $1.90 | $2.07 | $2.26 | +0.02% |
| Jul 17 | $1.88 | $2.07 | $2.28 | +0.02% |
| Jul 18 | $1.87 | $2.07 | $2.30 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.87 | $2.07 | $2.30 | +0.03% |
| Week 2 | $1.79 | $2.07 | $2.40 | +0.06% |
| Week 3 | $1.73 | $2.07 | $2.48 | +0.08% |
| Week 4 | $1.68 | $2.07 | $2.55 | +0.11% |
| Week 5 | $1.64 | $2.07 | $2.61 | +0.14% |
| Week 6 | $1.61 | $2.07 | $2.67 | +0.17% |
| Week 7 | $1.58 | $2.07 | $2.73 | +0.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Alaunos Therapeutics operates in the Healthcare sector, focusing on therapeutic candidates at an early stage of development. The description emphasizes its non-hormonal strategy and its platform for discovering TCR targets, highlighting a research-driven approach to metabolic and obesity-related conditions.
Alaunos Therapeutics, Inc. (TCRT) is currently priced at $2.08 per share with a market capitalization of $5.08M, and it is ranked 5174. The current price and rank place it among smaller biotechnology equities with a focus on obesity and metabolic disorders.
Forecasts envision a path of gradual price movement through 2026 and beyond, with 2026 average prices around $2.08 and a long-run trajectory toward higher levels, including a 2050 average near $9.94 and a possible max of $22.46. These figures imply meaningful upside opportunities over the extended horizon, though near-term results are more modest.
Technical context shows near-term levels and volatility that inform the price path. The 30-day range spans $1.56 to $2.77, with current indicators suggesting a neutral tone, and a volatility profile described at 80% annualized. Current moving averages place the price beneath longer-run averages, signaling an intermediate risk-reward backdrop for owners and potential entrants.
A major floor 38.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 47.8% above — a clean break opens room to run.
A major ceiling 76.3% above — clearing it would confirm fresh momentum.
Key TCRT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TCRT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.08 | Sell | $2.08 | Sell |
| MA 10 | $2.13 | Sell | $2.11 | Sell |
| MA 20 | $2.16 | Sell | $2.17 | Sell |
| MA 50 | $2.38 | Sell | $2.36 | Sell |
| MA 100 | $2.70 | Sell | $2.57 | Sell |
| MA 200 | $2.89 | Sell | $2.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.06 | Neutral |
| Stoch RSI (14) | 29.39 | Neutral |
| CCI (20) | -103.79 | Sell |
| Williams %R (14) | -96.97 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -4.65 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 3.03 | Buy |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 31.31 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 2.03 | Buy |
| ADX (14) | 18.47 | Neutral |
| ATR (14) | 0.07 | Info |
The near-term technical picture reads NEUTRAL with RSI(14) at 40. The stock trades relative to the moving averages, with SMA50 at $2.44 and SMA200 at $2.90. Support is identified at $1.97 and resistance at $3.06, providing a framework for potential short-term moves.
Over the last 30 days, the price has fluctuated within a range of $1.56 to $2.77, illustrating modest positive drift but respecting the established support and resistance levels. These signals suggest a cautious stance in the near term, with the possibility of moves toward the resistance as prices test the upper bound of the range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.97 | $2.07 | $2.81 | 0% | Neutral | |
| $1.47 | $1.93 | $2.70 | -7% | Neutral | |
| $1.56 | $2.13 | $3.14 | +3% | Neutral | |
| $1.77 | $2.50 | $3.83 | +21% | Bullish | |
| $1.99 | $2.90 | $4.59 | +40% | Bullish | |
| $2.06 | $3.10 | $5.04 | +50% | Bullish | |
| $1.75 | $2.70 | $4.50 | +30% | Bullish | |
| $1.78 | $2.82 | $4.81 | +36% | Bullish | |
| $1.83 | $2.98 | $5.19 | +44% | Bullish | |
| $1.64 | $2.72 | $4.83 | +31% | Bullish | |
| $2.06 | $3.83 | $7.36 | +85% | Bullish | |
| $3.81 | $8.46 | $18.17 | +309% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.97 | $2.07 | $2.53 | +0.00% |
| August 2026 | $1.71 | $2.04 | $2.52 | -1.25% |
| September 2026 | $1.72 | $2.08 | $2.61 | +1.63% |
| October 2026 | $1.83 | $2.23 | $2.83 | +7.15% |
| November 2026 | $1.83 | $2.25 | $2.89 | +0.92% |
| December 2026 | $1.75 | $2.17 | $2.81 | -3.62% |
Click any year to see its month-by-month TCRT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Alaunos Therapeutics, Inc.'s 2026 outlook centres on $2.07, within a $1.97 to $2.81 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TCRT could reach as high as $2.70, with a base case around $1.93 and support toward $1.47 — roughly -7% from $2.07. A consolidation phase looks the most probable path here.
Expect TCRT to range from $1.56 to $3.14 through 2028. The $2.13 average target implies a +3% move from current prices. That is up +11% on the projected 2027 average. Price action looks broadly range-bound.
The TCRT price prediction for 2029 points to an average of $2.50 (low $1.77, high $3.83) — a potential gain of +21% on today's $2.07. Buyers look set to stay in control over this stretch.
In 2030, TCRT is projected to trade between $1.99 and $4.59, averaging $2.90 — a potential gain of +40% from today's $2.07. That is up +16% on the projected 2029 average. Momentum favours further upside here.
Alaunos Therapeutics, Inc.'s 2031 outlook centres on $3.10, within a $2.06 to $5.04 range. That is up +7% on the projected 2030 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TCRT could reach as high as $4.50, with a base case around $2.70 and support toward $1.75 — roughly +30% from $2.07. Momentum favours further upside here.
Expect TCRT to range from $1.78 to $4.81 through 2033. The $2.82 average target implies a +36% move from current prices. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TCRT price prediction for 2034 points to an average of $2.98 (low $1.83, high $5.19) — a potential gain of +44% on today's $2.07. Momentum favours further upside here.
In 2035, TCRT is projected to trade between $1.64 and $4.83, averaging $2.72 — a potential gain of +31% from today's $2.07. That is -9% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Alaunos Therapeutics, Inc.'s 2040 outlook centres on $3.83, within a $2.06 to $7.36 range. That is up +41% on the projected 2035 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2050, TCRT could reach as high as $18.17, with a base case around $8.46 and support toward $3.81 — roughly +309% from $2.07. Buyers look set to stay in control over this stretch.
Investing $1,000 in TCRT today (≈ 483.091787 TCRT) could be worth
$4,087.69
+$3,087.69 (+309%) by 2050 · US Dollar
Based on the average projected TCRT price of $8.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TCRTwould be worth at today's price.
$1,000 invested in TCRT on Jul 10, 2025 (≈ 202.839764 TCRT) would be worth
$419.88
-$580.12 (-58.0%) today · 0.42× · US Dollar
Based on a TCRT entry price of $4.93 vs. today's $2.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.08 | $995.19 | -0.5% |
| 1 month ago | $1.97 | $1,050.76 | +5.1% |
| 3 months ago | $2.89 | $716.26 | -28.4% |
| 6 months ago | $2.85 | $726.32 | -27.4% |
| 1 year ago | $4.93 | $419.88 | -58.0% |
| All time (5.0y) ago | $366 | $5.66 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TCRT forecast.
Our base-case forecast reaches $4.10 around 2050.
Implied market cap at $4.10: $10.01M
The multi-year forecast paints a bullish trajectory beginning in the late 2020s. The 2026 forecast shows an avg of $2.08 with min $1.97 and max $2.89, and a ROI of 0, while 2027 reflects a dip to an avg of $1.97 (min $1.48, max $2.82) with a -5.2 ROI. The 2028 projection of $2.22 avg (min $1.59, max $3.35) yields a 6.6 ROI, followed by a stronger 2029 when the avg rises to $2.75 and the max to $4.34, a 32.4 ROI and a bullish sentiment.
Looking further, 2030 shows an avg of $3.18 with a max of $5.19 and a 52.9 ROI, and 2031 a further rise to $3.31 avg (max $5.57) with a 59.2 ROI. The 2040 forecast climbs to an avg of $4.18 and a max of $8.37, delivering a 100.7 ROI, while the 2050 target reaches an avg of $9.94 and a max of $22.46, with a 378 ROI and bullish sentiment throughout the long horizon. The forecast context includes an annualized volatility of 80%, underscoring the elevated risk associated with long-range projections.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $3.18, with a min of $2.11 and a max of $5.19, and a ROI of 52.9, with a BULLISH sentiment.
Forecasts show a mix of near-term softness and later upside. For example, 2027 projects an avg of $1.97 (ROI -5.2) after 2026 at $2.08 (ROI 0), while 2029 and beyond show higher avg prices and bullish sentiment. These are estimates, not guarantees, and reflect significant volatility (annualized volatility 80%).
Yes. The 2050 forecast lists an avg of $9.94 and a max of $22.46, implying a path that could reach around the mid-to-high single digits on average by 2050, with potential for higher outcomes.
The current price is $2.08.
The 30-day range has been between $1.56 and $2.77.
Alaunos Therapeutics, Inc. Community Discussion
0Share your Alaunos Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.